Radiopharm Theranostics Limited

Stage 4 · Declining · week 32

As of Oct 22, 2026, Radiopharm Theranostics is in Stage 4, the downtrend phase, now in week 32 (since Mar 6, 2026). It closed at $0.95, 91.1% below its 52-week high and below its 200-day average, which is falling.

$0.95

-2.94% today

$13.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is RADX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-12-05 → 2026-10-22

S? 42w

S4 33w

2024-12-052026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S2 7w → S3 6w → S4 5w → S1 3w → S2 1w → S1 1w → S4 33w current

Total tracked: 98 weeks across 8 stage runs.

RADX among Biotechnology496th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…496	RADXRadiopharm Theranostics Limited	Stage 4 · wk 32	9	−41.5%

vs 52W High

-91.1%

$0.95 lo$10.63 hi

91.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 32

1w13w26w

Week 32, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-75.0%

200 DMA: $3.80 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.26x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-41.5%

-73.2%

-79.0%

YTD

-81.6%

-84.3%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 32 · Vol 0.26x

2026-10-21S4

Wk 32 · Vol 0.24x

2026-10-20S4

Wk 32 · Vol 0.52x

2026-10-19S4

Wk 32 · Vol 0.21x

2026-10-16S4

Wk 32 · Vol 1.79x

2026-10-15S4

Wk 31 · Vol 1.10x

2026-10-14S4

Wk 31 · Vol 0.65x

2026-10-13S4

Wk 31 · Vol 2.41x

2026-10-12S4

Wk 31 · Vol 0.16x

2026-10-09S4

Wk 31 · Vol 1.08x

2026-10-08S4

Wk 30 · Vol 0.43x

2026-10-07S4

Wk 30 · Vol 0.66x

Moving averages & range

50 DMA

$1.77

200 DMA

$3.80

52W High

$10.63

52W Low

$0.95

5D Low

$0.95

Resistance levels (recent highs)

20d High

$1.65

60d High

$3.20

120d High

$4.75

250d High

$10.63

Next resistance

+73.7%

to 20d High

ROE

-174.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.6

Radiopharm Theranostics: quick answers

What stage is Radiopharm Theranostics in?

As of Oct 22, 2026, Radiopharm Theranostics (RADX) is in Stage 4, the downtrend phase. It entered Stage 4 on Mar 6, 2026 and is in week 32. What the four stages mean

Is Radiopharm Theranostics in an uptrend?

No. Radiopharm Theranostics is in a Stage 4 downtrend. It trades 75.0% below its 200-day average, which is falling.

How far is Radiopharm Theranostics from its 52-week high?

Radiopharm Theranostics closed at $0.95 on Oct 22, 2026, 91.1% below its 52-week high of $10.63. Its 52-week low is $0.95.

How has Radiopharm Theranostics performed over the past year?

As of Oct 22, 2026, Radiopharm Theranostics is down 84.3% over the past year and down 81.6% so far in 2026.

Which sector and industry is Radiopharm Theranostics in?

Radiopharm Theranostics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.